Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.…
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Citius Pharmaceuticals (NASDAQ: CTXR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 23 employees.
The shares were at 0.5085 USD on 20 November 2026, down 59.3% over 52 weeks. Its 52-week range is 0.3699 USD to 1.540 USD: the price is 67.0% below the high and 37.5% above the low.
Its market capitalisation is 13.96M USD.
Citius Pharmaceuticals reports return on equity of -55.4%.
It holds more cash than debt, a net cash position of 9.83M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 29 December 2026.